Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Osaka Univ. Professor, Mitsubishi Tanabe Receive Prime Minister’s R&D Award for Contributions to Development of SGLT2 Inhibitor
January 14, 2020
- MHLW to Beef Up GMP Inspections at API Manufacturing Sites in Asia from FY2020 in Response to Series of Supply Disruptions
January 6, 2020
- MHLW Revises Safety Guidance on FIH Studies Following Death of Subject
January 6, 2020
- MHLW to Set Up New Study Group on Detailing Activities Report System for All Medical Institutions
January 6, 2020
- JETRO’s New York Office Gets First Health and Welfare Head in 2 Years
January 1, 2020
- Councilor Mori Urges Drug Maker Management to Straighten Up as He Bids Farewell to MHLW
December 27, 2019
- Health Ministry Panel Calls for Simplified Certification Process for Vaccines to Ensure Stable Supplies
December 27, 2019
- Japan Lays Out Action Plan for Whole Genome Analysis; Preliminary Project to Cover 64,000 Cancer Patients, 28,000 for Intractable Diseases
December 27, 2019
- AMED’s Kono Tapped to Lead Medical Device Review at MHLW
December 26, 2019
- Japan's Global Health Confab to Prepare New Grand Design for Regulatory Harmonization in Asia
December 26, 2019
- MHLW to Establish Clinical Research Centers for Pediatric, Rare Diseases: FY2020 Budget
December 25, 2019
- 930 Million Yen Allocated for Amended PMD Law-Related Projects: MHLW Pharma Safety Bureau
December 24, 2019
- Fumi Yamamoto 1st Woman to Become MHLW’s Top Pharmacy Officer
December 23, 2019
- Govt’s All-Generation Social Security Panel Compiles Interim Report, No Mention of OTC-Like Drugs
December 23, 2019
- Japan OKs FY2020 Budget, Record 35.86 Trillion Yen Allotted to Social Security
December 23, 2019
- Japan Approves Keytruda’s 1st Line RCC, Head and Neck Cancer Use, Bavencio’s Label Expansion and More
December 23, 2019
- MHLW Panel Concerned about Further Clinical Trial for Eisai’s Investigational Epilepsy Drug Following Death
December 23, 2019
- Japan to Shave Drug Spending by 4.38% in FY2020 Price Revision: MHLW
December 20, 2019
- Japan Panel Hammers Out FY2020 Drug Pricing Reform
December 20, 2019
- MHLW Council Holds Off Nonprescription Switches for Domperidone, Menatetrenone
December 20, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…